Phio Pharmaceuticals (PHIO) EBITDA Margin (2012 - 2019)

Phio Pharmaceuticals (PHIO) has reported EBITDA Margin for 8 consecutive years, with 10219.05% the latest figure, recorded in Q1 2019.

• For the quarter ending Q1 2019, EBITDA Margin fell 48427.0% year-over-year to 10219.05%; the trailing twelve-month figure through Dec 2019 stood at 42795.24% (down 3745901.0% YoY), and the FY2019 full-year result was 42795.24%, down 3745901.0% from the prior year.
• EBITDA Margin retreated to 10219.05% in Q1 2019 per PHIO's latest filing, from 2617.54% in the prior quarter.
• Across five years, EBITDA Margin topped out at 2617.54% in Q3 2018 and bottomed at 24611.11% in Q2 2016.
• Historically, EBITDA Margin has averaged 11855.58% across 5 years, with a median of 9976.92% in 2018.
• The sharpest annual moves came in 2016 and 2019: EBITDA Margin slumped 1378529 bps in 2016, then tumbled 48427 bps in 2019.
• Over 5 years, EBITDA Margin stood at 8664.71% in 2015, then tumbled by 184 bps to 24611.11% in 2016, then surged by 46 bps to 13273.33% in 2017, then jumped by 80 bps to 2617.54% in 2018, then sank by 290 bps to 10219.05% in 2019.
• According to Business Quant data, EBITDA Margin over the past three periods registered 10219.05%, 2617.54%, and 3274.14% for Q1 2019, Q3 2018, and Q2 2018 respectively.